Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit — Drug Approvals & Catalyst Tracker
Decision brief
Answer first · skim in under a minute
Pfizer, Hikma Pharmaceuticals, and NewLimit are at the center of recent FDA actions. This rundown covers approvals, withdrawals, and upcoming catalysts for pharma BD and investors.
Rundown Pfizer Hikma Pharmaceuticals NewLimit catalysts for mid-2026: Pfizer's Hympavzi hemophilia expansion, a Federal Register withdrawal of 29 NDAs involving Hikma, and a correction that giredestrant belongs to Roche—not Pfizer—plus NewLimit's still-preclinical status.
Contents9 sections
Key Takeaways
- Pfizer Hympavzi expanded on June 8, 2026 to ages 6+ with or without inhibitors (Priority Review).
- FDA withdrew 29 NDAs effective March 4, 2022 after sponsors said products were no longer marketed.
- Giredestrant NDA acceptance is a Roche/Genentech event (PDUFA expected November 30, 2026 for adjuvant).
- NewLimit remains preclinical; no FDA approval or public IND acceptance is cited here.
What did FDA approve for Pfizer Hympavzi?
Pfizer announced on June 8, 2026 that FDA approved an expanded indication for Hympavzi (marstacimab-hncq). The product is now indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients 6 years and older with hemophilia A or B, with or without factor inhibitors.
According to the Pfizer press release, the application received Priority Review. FDA also granted Breakthrough Therapy Designation for routine prophylaxis in younger pediatric (≥6 to <12) patients with hemophilia B with and without inhibitors. Supporting trials include BASIS (NCT03938792) and BASIS KIDS (NCT05611801).
What does the Hikma NDA withdrawal notice say?
On February 2, 2022, FDA published a Federal Register notice withdrawing approval of 29 new drug applications from multiple applicants, including Hikma Pharmaceuticals USA, Inc. Applicants had notified FDA in writing that the products were no longer marketed and requested withdrawal under 21 CFR 314.150(c).
The govinfo Federal Register text (FR Doc 2022-02059) states approval was withdrawn as of March 4, 2022. That is a housekeeping withdrawal of discontinued marketed products, not a 2026 safety recall.
Why correct the giredestrant attribution?
Earlier drafts of this rundown incorrectly assigned giredestrant to Pfizer. Primary company releases show Genentech/Roche own the asset. Roche said FDA accepted an NDA under Priority Review for giredestrant as adjuvant treatment in ER-positive, HER2-negative early breast cancer, with an expected decision by November 30, 2026.
See the Roche media release. The lidERA Breast Cancer trial is registered as NCT04961996. A separate Roche NDA for giredestrant plus everolimus in ESR1-mutated advanced disease carries an expected decision around December 18, 2026.
Where does NewLimit stand with FDA?
NewLimit is a private longevity company developing epigenetic reprogramming approaches. Company and secondary coverage describe a large 2026 financing and plans for first human dosing around 2027, but this rundown does not treat fundraising blogs as regulatory milestones. Until an IND is accepted and posted, NewLimit has no FDA drug approval catalyst.
What remains unproven?
Hympavzi's expanded label does not by itself forecast U.S. share versus other non-factor prophylactics. Hikma's 2022 NDA withdrawals do not imply a new 2026 enforcement wave without fresh FDA notices. Roche's giredestrant filings remain under review until the stated 2026 action dates.
Related NovaPharma coverage
- Pfizer berobenatide obesity drug Vesper-3 data
- Pfizer berobenatide monthly obesity Phase 2b data
- Danuglipron Phase 3 and Pfizer obesity trial
Frequently Asked Questions
What Pfizer FDA action is in this rundown?
On June 8, 2026, Pfizer said FDA approved an expanded Hympavzi (marstacimab-hncq) indication covering routine prophylaxis in patients 6 years and older with hemophilia A or B, with or without inhibitors.
What happened to Hikma Pharmaceuticals NDAs?
A February 2, 2022 Federal Register notice (FR Doc 2022-02059) withdrew approval of 29 NDAs, including Hikma Pharmaceuticals USA products, after applicants told FDA the drugs were no longer marketed. Withdrawal was effective March 4, 2022.
Is giredestrant a Pfizer drug?
No. Giredestrant is a Roche/Genentech oral SERD. Roche said FDA accepted an NDA under priority review for adjuvant ER-positive early breast cancer with an expected decision by November 30, 2026.
Primary Sources
Pfizer pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
